A BILL 
To amend title XVIII of the Social Security Act to provide 
coverage under the Medicare program for FDA-approved 
qualifying colorectal cancer screening blood-based tests, 
18:45 May 07, 2021
H1655
2 
•HR 1655 IH
to increase participation in colorectal cancer screening 
in under-screened communities of color, to offset the 
COVID-19 pandemic driven declines in colorectal cancer 
screening, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Donald Payne Sr. 
4
Colorectal Cancer Detection Act of 2021’’. 
5
SEC. 2. MEDICARE COVERAGE FOR FDA-APPROVED QUALI-
6
FYING 
COLORECTAL 
CANCER 
SCREENING 
7
BLOOD-BASED TESTS. 
8
(a) IN GENERAL.—Section 1861(pp) of the Social Se-
9
curity Act (42 U.S.C. 1395x(pp)) is amended— 
10
(1) in paragraph (1)— 
11
(A) by redesignating subparagraph (D) as 
12
subparagraph (E); and 
13
(B) by inserting after subparagraph (C) 
14
the following new subparagraph: 
15
‘‘(D) Qualifying colorectal cancer screening 
16
blood-based test.’’; and 
17
(2) by adding at the end the following new 
18
paragraph: 
19
‘‘(3) The term ‘qualifying colorectal cancer screening 
20
blood-based test’ means, with respect to a year, a screen-
21
ing blood-based test for the early detection of colorectal 
22
18:45 May 07, 2021
H1655
3 
•HR 1655 IH
cancer furnished in the year that was marketed or used, 
1
as applicable, in accordance with the relevant provisions 
2
of section 353 of the Public Health Service Act or the 
3
Federal Food, Drug, and Cosmetic Act more than 6 
4
months before the beginning of the year.’’. 
5
(b) FREQUENCY LIMITS FOR COLORECTAL CANCER 
6
SCREENING TESTS AND PAYMENT AMOUNT FOR QUALI-
7
FYING COLORECTAL CANCER SCREENING BLOOD-BASED 
8
TESTS.—Section 1834(d) of the Social Security Act (42 
9
U.S.C. 1395m(d)) is amended— 
10
(1) by amending clause (ii) of paragraph (1)(B) 
11
to read as follows: 
12
‘‘(ii) if the test is performed within— 
13
‘‘(I) the 11 months after a pre-
14
vious screening fecal-occult blood test 
15
or a previous qualifying colorectal 
16
cancer screening blood-based test; 
17
‘‘(II) the 35 months after a pre-
18
vious screening flexible sigmoidoscopy 
19
or a previous screening colonoscopy 
20
with adenoma findings; 
21
‘‘(III) the 59 months after a pre-
22
vious screening colonoscopy with small 
23
polyp findings; or 
24
18:45 May 07, 2021
H1655
4 
•HR 1655 IH
‘‘(IV) the 119 months after a 
1
previous screening colonoscopy with-
2
out adenoma findings or small polyp 
3
findings.’’; 
4
(2) in paragraph (2)(E)(ii), by inserting ‘‘or 
5
within the 35 months after a previous screening 
6
fecal-occult 
blood 
test 
or 
previous 
qualifying 
7
colorectal cancer screening blood-based test’’ after 
8
‘‘sigmoidoscopy’’; 
9
(3) by amending subparagraph (E) of para-
10
graph (3) to read as follows: 
11
‘‘(E) FREQUENCY
LIMIT.—No payment 
12
may be made under this part for a colorectal 
13
cancer screening test consisting of a screening 
14
colonoscopy— 
15
‘‘(i) if the procedure is performed 
16
within the 11 months after a previous 
17
screening fecal-occult blood test or previous 
18
qualifying 
colorectal 
cancer 
screening 
19
blood-based test; 
20
‘‘(ii) for individuals at high risk for 
21
colorectal cancer if the procedure is per-
22
formed within the 23 months after a pre-
23
vious screening colonoscopy; or 
24
18:45 May 07, 2021
H1655
5 
•HR 1655 IH
‘‘(iii) for individuals not at high risk 
1
for colorectal cancer if the procedure is 
2
performed within the 119 months after a 
3
previous screening colonoscopy or within 
4
the 47 months after a previous screening 
5
flexible sigmoidoscopy.’’; and 
6
(4) by adding at the end the following new 
7
paragraph: 
8
‘‘(4) 
QUALIFYING
COLORECTAL
CANCER 
9
SCREENING BLOOD-BASED TESTS.— 
10
‘‘(A) PAYMENT
AMOUNT.—The payment 
11
amount for colorectal cancer screening tests 
12
consisting of qualifying colorectal cancer screen-
13
ing blood-based tests shall be established by the 
14
Secretary. 
15
‘‘(B) 
FREQUENCY
LIMIT.—Paragraph 
16
(1)(B) shall apply to colorectal cancer screening 
17
tests consisting of qualifying colorectal cancer 
18
screening blood-based tests in the same manner 
19
as such paragraph applies to colorectal cancer 
20
screening tests consisting of fecal-occult blood 
21
tests.’’. 
22
(c) EFFECTIVE DATE.—The amendments made by 
23
this section shall apply to colorectal cancer screening tests 
24
18:45 May 07, 2021
H1655
6 
•HR 1655 IH
furnished in a year beginning more than 6 months after 
1
the date of the enactment of this Act. 
2
Æ 
18:45 May 07, 2021
H1655
